Luis E. Ortiz-Muñoz

Luis E. Ortiz-Muñoz

Auto-generated profile, based on publicly available information

Luis E. Ortiz-Muñoz

UC Evidence Center, Cochrane Chile Associated Center, Pontificia Universidad Catolica de Chile, Santiago, Chile

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2021 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
PDF file
LVLaura Vergara‐Merino
Laura Vergara‐Merino
NMNicolás Meza
Nicolás Meza
CCConstanza Couve‐Pérez
Constanza Couve‐Pérez
CCCynthia Carrasco
Cynthia Carrasco
LOLuis Ortiz‐Muñoz
Luis Ortiz‐Muñoz
JBJavier Bracchiglione
Javier Bracchiglione
Introduction: Evidence about coronavirus disease 2019 (COVID‐19) and pregnancy has rapidly increased since December 2019, making it difficult to make rigorous evidence‐based decisions. The objective of this overview of systematic reviews is to conduct a comprehensive analysis of the current evidence on prognosis of COVID‐19 in pregnant women.Material and methods: We used the Living OVerview of Evidence (L·OVE) platform for COVID‐19, which continually retrieves studies from 46 data sources (including PubMed/MEDLINE, Embase, other electronic databases, clinical trials registries, and preprint repositories, among other sources relevant to COVID‐19), mapping them into PICO (population, intervention, control, and outcomes) questions. The search covered the period from the inception date of each database to 13 September 2020. We included systematic reviews assessing outcomes of pregnant women with COVID‐19 and/or their newborns. Two authors independently screened the titles and abstracts, assessed full texts to select the studies that met the inclusion criteria, extracted data, and appraised the risk of bias of each included systematic review. We measured the overlap of primary studies included among the selected systematic reviews by building a matrix of evidence, calculating the corrected covered area, and assessing the level of overlap for every pair of systematic reviews.Results: Our search yielded 1132 references. 52 systematic reviews met inclusion criteria and were included in this overview. Only one review had a low risk of bias, three had an unclear risk of bias, and 48 had a high risk of bias. Most of the included reviews were highly overlapped among each other. In the included reviews, rates of maternal death varied from 0% to 11.1%, admission to intensive care from 2.1% to 28.5%, preterm deliveries before 37 weeks from 14.3% to 61.2%, and cesarean delivery from 48.3% to 100%. Regarding neonatal outcomes, neonatal death varied from 0% to 11.7% and the estimated infection status of the newborn varied between 0% and 11.5%.Conclusions: Only one of 52 systematic reviews had a low risk of bias. Results were heterogeneous and the overlap of primary studies was frequently very high between pairs of systematic reviews. High‐quality evidence syntheses of comparative studies are needed to guide future clinical decisions.

31 July 2021 in Medwave
Verified
Journal Article
Closed access
CGCatalina Gracia González-Xuriguera
Catalina Gracia González-Xuriguera
LVLaura Vergara-Merino
Laura Vergara-Merino
LGLuis Garegnani
Luis Garegnani
LOLuis Ortiz-Muñoz
Luis Ortiz-Muñoz
NMNicolás Meza
Nicolás Meza
This article belongs to a collaborative methodological series of narrative reviews about biostatistics and clinical epidemiology. The goal is to present basics concepts concerning the systematics reviews of multiple treatments comparisons with network meta-analysis. For clinical ques-tions with several therapeutic alternatives to be compared, the central question is how to classify or rank their effectiveness (benefit and harm) to choose the best option. The network meta-analysis aims to answer questions related to the effectiveness and safety of comparing multiple treatments by the simultaneous analysis of results raised from direct and indirect comparisons. The network geometry is the general graphical representation of the network meta-analysis and allows to understand and assess the strength of comparisons. The network meta-analysis should check several assumptions to be valid, especially the transitivity assumption, which allows assuming that there are no systematic differences among the included comparisons, except their compared interventions. Thus, it is possible to know the relative therapeutic effectiveness of each pair of interventions included in the network meta-analysis and their ranking in terms of categorization. It has been proposed to use a modified Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach considering the distinctive features of network meta-analysis to assess the certainty of the evidence for each comparison and the ranking of interventions.

31 July 2020 in Medwave
Verified
Journal Article
Closed access
Eduard BaladiaEduard Baladia
Eduard Baladia
APAna Beatriz Pizarro
Ana Beatriz Pizarro
LOLuis Ortiz-Muñoz
Luis Ortiz-Muñoz
GRGabriel Rada
Gabriel Rada
This living systematic review aims to provide a timely, rigorous, and continuously updated summary of the available evidence on the role of vitamin C in treating patients with COVID-19. We conducted searches in PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature, and in a centralized repository in L·OVE (Living OVerview of Evidence). In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence it comprises and has been customized to group all COVID-19 evidence in one place. All the searches covered the period until April 29, 2020 (one day before submission). We adapted an already published standard protocol for multiple parallel systematic reviews. We searched for randomized trials evaluating the effect, in patients with COVID-19, of vitamin C versus placebo or no treatment. Anticipating the lack of randomized trials directly addressing this question, we also searched for trials evaluating MERS-CoV and SARS-CoV, and non-randomized studies in COVID-19. Two reviewers independently screened each study for eligibility. A living, web-based version of this review will be openly available during the COVID-19 pandemic, and we will resubmit it to the journal whenever there are substantial updates. We screened 95 records, but no study was considered eligible. We identified 20 ongoing studies, including 13 randomized trials evaluating vitamin C in COVID-19. We did not find any studies that met our inclusion criteria, and hence there is no evidence to support or refute the use of vitamin C in the treatment of patients with COVID-19. A substantial number of ongoing studies should provide valuable evidence to inform researchers and decision-makers soon. CRD42020181216.

23 February 2021 in Medwave
Verified
Journal Article
Open access
LTLuis Tapia-Benavente
Luis Tapia-Benavente
LVLaura Vergara-Merino
Laura Vergara-Merino
LGLuis Ignacio Garegnani
Luis Ignacio Garegnani
LOLuis Ortiz-Muñoz
Luis Ortiz-Muñoz
CHCristóbal Loézar Hernández
Cristóbal Loézar Hernández
MVManuel Vargas-Peirano
Manuel Vargas-Peirano
This article is the first in a collaborative methodological series of narrative reviews on biostatistics and clinical epidemiology. This review aims to present rapid reviews, compare them with systematic reviews, and mention how they can be used. Rapid reviews use a methodology like systematic reviews, but through shortcuts applied, they can attain answers in less than six months and with fewer resources. Decision-makers use them in both America and Europe. There is no consensus on which shortcuts have the least impact on the reliability of conclusions, so rapid reviews are heterogeneous. Users of rapid reviews should identify these shortcuts in the methodology and be cautious when interpreting the conclusions, although they generally reach answers concordant with those obtained through a formal systematic review. The principal value of rapid reviews is to respond to health decision-makers’ needs when the context demands answers in limited time frames.

21 January 2025 in Medwave
Verified
Journal Article
Closed access
GDGiuliano Duarte
Giuliano Duarte
YOYasmina Okan
Yasmina Okan
MJMarie Johnston
Marie Johnston
LOLuis Ortiz
Luis Ortiz
Pablo VillalobosDintransPablo VillalobosDintrans
Pablo VillalobosDintrans
MRManuel Armayones Ruiz
Manuel Armayones Ruiz
The World Health Organization (WHO) highlights the importance of improving the design of public health interventions and policies by applying principles from the behavioral sciences. These sciences play a crucial role in modifying behaviors and addressing a wide range of health challenges, from pandemics and chronic diseases to the climate crisis. This article examines the transformative impact of behavioral sciences on public health promotion, focusing on the factors that influence decision-making and intervention strategies based on the six principles developed by the WHO Technical Advisory Group. Additionally, it addresses the significant shortage of Spanish-language literature on this topic, reviewing contributions from influential scientists and key theoretical models. The WHO’s recommendations for the effective implementation of these interventions in public health are also discussed. This work not only fills a critical gap in the Spanish-language literature but also provides practical tools to improve public health in Spanish-speaking countries.

26 June 2018 in Medwave
Verified
Journal Article
Open access
DUDiego Ubilla
Diego Ubilla
JAJoaquín Ananías
Joaquín Ananías
LOLuis Ortiz-Muñoz
Luis Ortiz-Muñoz
SISebastián Irarrázaval
Sebastián Irarrázaval
Despite varied non-surgical alternatives for the treatment of osteoarthritis, many patients remain symptomatic. In the last decade, the use of intra-articular platelet-rich plasma (PRP) has been proposed as an option. However, there is controversy about its clinical benefit and safety. To answer this question we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. We identified twelve systematic reviews including four studies overall, of which all corresponded to randomized trials. We concluded that intra-articular injection of platelet-rich plasma might slightly decrease joint pain and improve patient satisfaction,vut it is not clear whether it has any effect on functionality because the certainty of the evidence is very low. As for the adverse effects, if they exist, they would be non-severe and self-limited.